Assessment Of The Acute On Chronic Liver Failure (ACLF) Market 2026-2036: YAQ005, SRT-015 And G1090N Lead The Emerging ACLF Pipeline
Dublin, Sept. 08, 2026 (GLOBE NEWSWIRE) -- The "Acute on Chronic Liver Failure (ACLF) - Market Insight, Epidemiology, and Market Forecast - 2036" has been added to ResearchAndMarkets.com's offering.
The report provides a comprehensive assessment of the ACLF market across the seven major markets (7MM): the United States, Germany, France, Italy, Spain, the United Kingdom and Japan. Covering historical and forecast data from 2022 to 2036, the report examines patient burden, treatment practices, market dynamics, emerging therapies, drug uptake, reimbursement and commercial opportunities.
The acute-on-chronic liver failure market is expected to expand during the forecast period, driven by the growing burden of chronic liver disease, greater diagnostic awareness and demand for therapies capable of addressing systemic inflammation, immune dysregulation and multi-organ failure. Alcohol-related liver disease represents a major underlying contributor, while viral hepatitis, nonalcoholic steatohepatitis, sepsis, renal dysfunction and metabolic disorders also contribute substantially to ACLF incidence and clinical complexity.
ACLF Treatment Landscape and Unmet Medical Need
No targeted therapy is currently approved specifically for ACLF. Clinical management remains multidisciplinary and primarily includes intensive supportive care, infection control, albumin infusion, renal replacement therapy, plasma exchange and mechanical ventilation when required. Frequently used pharmacological interventions include antibiotics, hepatitis B antivirals such as entecavir and tenofovir disoproxil fumarate, terlipressin for hepatorenal syndrome, lactulose and rifaximin for hepatic encephalopathy, and prednisolone for selected patients with alcohol-associated hepatitis.
Liver transplantation remains the definitive treatment for eligible patients with advanced ACLF. However, donor shortages, cost, clinical eligibility requirements and limited access restrict its availability. Major unmet needs include:
- Targeted therapies capable of reversing hepatic and multi-organ dysfunction Improved short-term survival despite intensive supportive care Earlier diagnosis and reliable prognostic biomarkers Broader access to liver transplantation and specialist treatment centers Effective strategies for infection control, organ protection and immune regulation
Regional prognostic systems, including the Chronic Liver Failure Consortium ACLF score, the APASL ACLF Research Consortium score and the North American Consortium for the Study of End-Stage Liver Disease criteria, support mortality assessment, treatment planning and transplantation decisions.
Emerging ACLF Pipeline and Competitive Landscape
The ACLF clinical pipeline remains limited but includes mechanism-driven programs targeting inflammation, the gut-liver axis, immune dysfunction and organ injury. Companies active in the emerging acute-on-chronic liver failure treatment landscape include Yaqrit Discovery, Seal Rock Therapeutics, GENFIT, Celloram, CRISPR Medicine Media and Miromatrix Medical.
Leading investigational candidates include:
- YAQ005 by Yaqrit Discovery: An orally administered, non-absorbable carbon-based adsorbent designed to reduce endotoxins, inflammatory mediators and gut-derived harmful substances associated with systemic inflammation and organ dysfunction. SRT-015 by Seal Rock Therapeutics and GENFIT: An investigational apoptosis signal-regulating kinase 1 inhibitor targeting inflammatory and cellular stress pathways associated with hepatocellular injury and multi-organ failure. G1090N by GENFIT: An investigational nitazoxanide-based therapy under evaluation within the emerging ACLF pipeline.
Additional early-stage programs include CLM-022 and bbHEP01, while device-based approaches such as miroliverELAP and YAQ002 are also under investigation. In December 2025, the Grifols Therapeutics-sponsored APACHE trial was terminated for corporate business reasons unrelated to safety. In September 2025, GENFIT discontinued the development of VS-01 in ACLF following a serious adverse event in a Phase II study.
Acute-on-Chronic Liver Failure Market Outlook
The ACLF treatment market is shifting from conventional supportive care toward targeted anti-inflammatory, immunomodulatory, gut-directed and regenerative approaches. Supportive therapies and liver transplantation currently account for the principal components of treatment, while pipeline innovation increasingly focuses on reducing bacterial translocation, modulating cytokine activity, protecting organ function and promoting hepatic repair.
The United States is expected to retain a leading share of the 7MM ACLF market, supported by its patient burden, specialist infrastructure, research activity, diagnostic capabilities and access to transplantation services. Europe and Japan are also expected to demonstrate increasing clinical and commercial interest as awareness improves and novel treatment strategies advance through development.
The report evaluates ACLF market size, therapy-level market share, patient uptake, peak patient share, pricing, analogue assessment and sales forecasts through 2036. It also examines country-specific reimbursement, cost-effectiveness, insurance coverage, patient affordability and market access considerations that may influence the adoption of emerging ACLF therapies.
Report Coverage and Strategic Insights
The analysis incorporates epidemiology-based bottom-up forecasting, patient population estimates, treatment algorithms, clinical development activity and competitive intelligence. Primary research includes perspectives from key opinion leaders and subject-matter experts associated with institutions such as the University of Mississippi Medical Center, the University of Bologna and Teikyo University School of Medicine.
Key areas covered in the acute-on-chronic liver failure market report include:
- Historical and forecast ACLF epidemiology across the 7MM Current treatment practices and evolving therapeutic algorithms ACLF market size, growth trends and commercial opportunities through 2036 Pipeline analysis and profiles of emerging ACLF drugs and technologies Drug uptake, adoption, pricing and reimbursement forecasts Competitive assessment of established and emerging ACLF companies SWOT and conjoint analysis of leading therapeutic candidates Patient journey, unmet needs and market access barriers
The findings are designed to support pharmaceutical companies, biotechnology developers, investors and healthcare stakeholders in identifying growth opportunities, prioritizing pipeline assets and developing evidence-based clinical, commercialization and market access strategies for the evolving acute-on-chronic liver failure market.
A selection of companies mentioned in this report includes, but is not limited to:
- Yaqrit Discovery Seal Rock Therapeutics GENFIT
For more information about this report visit
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept any
responsibility or liability for the accuracy, content, images, videos,
licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright issues
related to this article, kindly contact the provider above.
Comments
No comment